Christina (Tina) P./LinkedIn
Sep 14, 2026, 04:43
Christina (Tina) P.: Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Christina (Tina) P., CEO and Co-Founder of APS Foundation of America, shared on LinkedIn:
“Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis
Eye damage remains uncommon after 15 years, but certain factors increase the risk by John Gever, Contributing Writer, MedPage Today.
A recent meta-analysis details that the risk of retinopathy from long-term hydroxychloroquine (HCQ) treatment remains low initially but increases significantly after decades of continuous use.
Clinical guidelines recommend baseline eye exams and annual ophthalmologic screenings after five years of use to prevent permanent vision loss.
More posts featuring Christina (Tina) P. on Hemostasis Today.
-
Nov 2, 2026, 22:15Micheline Mambue: A Case of Early Stent Thrombosis Successfully Managed With Repeat Angioplasty
-
Nov 2, 2026, 22:12Annie Bauzon: How the Body Produces Millions of Blood Cells Every Day
-
Nov 2, 2026, 22:11Anna Supernat: Does Leukocyte-Associated RNA Retention Affect Platelet-Based Cancer Classification?
-
Nov 2, 2026, 22:07Aabha Divya: Late Biatrial Thrombosis 31 Years After Heart Transplantation
-
Nov 2, 2026, 22:01Sakditad Saowapa: Anticoagulant Pharmacology and the Pursuit of Effective Therapy With Less Bleeding
-
Nov 2, 2026, 21:55Lucio D’Anna: Can Inflammatory Biomarkers Identify Residual Risk in Atrial Fibrillation?
-
Nov 2, 2026, 21:54Dawood Findakly: VTE Prophylaxis during Pregnancy
-
Nov 2, 2026, 21:52N. Mariana S. Vasquez: Five Rules That Help Identify the Cause of Hemolytic Anemia
-
Nov 2, 2026, 21:52Rob Maloney: Working Together to Strengthen Bleeding Disorders Care in the Dominican Republic